From Sept 22 Ann
These revised clinical plans have substantially reduced the Company's budgeted trial costs, and with the expected additional R&D tax incentive rebates, the Company now estimates that it can fund both the Company and the trial into 4Q’23.
Ann: Chief Executive Officer and Managing Director Appointment, page-36
-
- There are more pages in this discussion • 72 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
